RJA
ADVM

Raymond James & Associates’s Adverum Biotechnologies ADVM Stock Holding History

Raymond James & Associates’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,900
Closed -$172K – 3465
2017
Q4 		$172K Buy
+4,900
New +$161K ﹤0.01% 3107

Other funds holding ADVM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Raymond James & Associates's ADVM Position: Q1 2018 in Review

Raymond James & Associates sold out of Adverum Biotechnologies (ADVM) in Q1 2018, closing a stake of 4,900 shares — an estimated $172K sold.

Raymond James & Associates first reported a position in ADVM in Q4 2017 and held it in 1 quarter. The position peaked at $172K in Q4 2017. 96 funds tracked by Wall St. Rank hold ADVM as of Q1 2018.

  • Raymond James & Associates reported no remaining Adverum Biotechnologies position as of Q1 2018 after selling out during the quarter.
  • Raymond James & Associates sold 4,900 Adverum Biotechnologies shares in Q1 2018, an estimated $172K.
  • Raymond James & Associates first reported a position in Adverum Biotechnologies in Q4 2017 and held it in 1 quarter.
  • Raymond James & Associates's Adverum Biotechnologies position peaked at $172K in Q4 2017.
  • 96 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2018.

Based on Raymond James & Associates's 13F filing for Q1 2018, filed 14 May 2018.